Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Chase

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Blood|November 5, 2011
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsJoannah Score, Claire Hidalgo-Curtis, Amy V Jones, et al.
Leukemia Research|December 16, 2014
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasmsAmy V Jones, Daniel Ward, Matthew Lyon, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Annals of Hematology|September 28, 2014
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesJuliana Schwaab, Marcin Knut, Claudia Haferlach, et al.
European Journal of Human Genetics : EJHG|November 23, 2020
Pathogenic variants causing ABL1 malformation syndrome cluster in a myristoyl-binding pocket and increase tyrosine kinase activityAlexander J M Blakes, Emily Gaul, Wayne Lam, et al.
Leukemia|December 22, 2018
PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasiaAndrew Chase, Andrea Pellagatti, Shalini Singh, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Cancer Research|April 5, 2005
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Andreas Reiter, Christoph Walz, Ann Watmore, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Leukemia|December 22, 2018
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophiliaNicholas C P Cross, Yvette Hoade, William J Tapper, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Blood|November 5, 2011
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsJoannah Score, Claire Hidalgo-Curtis, Amy V Jones, et al.
Leukemia Research|December 16, 2014
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasmsAmy V Jones, Daniel Ward, Matthew Lyon, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Annals of Hematology|September 28, 2014
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesJuliana Schwaab, Marcin Knut, Claudia Haferlach, et al.
European Journal of Human Genetics : EJHG|November 23, 2020
Pathogenic variants causing ABL1 malformation syndrome cluster in a myristoyl-binding pocket and increase tyrosine kinase activityAlexander J M Blakes, Emily Gaul, Wayne Lam, et al.
Leukemia|December 22, 2018
PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasiaAndrew Chase, Andrea Pellagatti, Shalini Singh, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Cancer Research|April 5, 2005
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2Andreas Reiter, Christoph Walz, Ann Watmore, et al.
Blood|September 9, 2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disordersMarianna David, Nicholas C P Cross, Sonja Burgstaller, et al.
Leukemia|December 22, 2018
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophiliaNicholas C P Cross, Yvette Hoade, William J Tapper, et al.
Pageof 4